Revolution Medicines (NASDAQ:RVMD) COO Margaret Horn Sells 4,775 Shares

Key Points

• Revolution Medicines' COO Margaret Horn sold 4,775 shares of stock at an average price of $45.82, decreasing her ownership in the company by 3.17%.
• The company's shares recently traded at $45.28 with a market capitalization of $8.46 billion and a debt-to-equity ratio of 0.13.
• Analysts have generally rated Revolution Medicines as a "Buy," with an average price target of $73.67 and recent upgrades from firms such as Wedbush and Wells Fargo.

Revolution Medicines, Inc. (NASDAQ:RVMD - Get Free Report) COO Margaret Horn sold 4,775 shares of Revolution Medicines stock in a transaction dated Tuesday, September 16th. The shares were sold at an average price of $45.82, for a total transaction of $218,790.50. Following the sale, the chief operating officer owned 145,900 shares in the company, valued at approximately $6,685,138. This trade represents a 3.17% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through this hyperlink.

Revolution Medicines Price Performance

Shares of Revolution Medicines stock traded up $1.47 during trading on Thursday, hitting $45.28. 1,764,773 shares of the company's stock traded hands, compared to its average volume of 1,902,022. The company has a debt-to-equity ratio of 0.13, a current ratio of 11.79 and a quick ratio of 11.79. The firm's fifty day moving average price is $38.40 and its 200 day moving average price is $38.29. Revolution Medicines, Inc. has a twelve month low of $29.17 and a twelve month high of $62.40. The company has a market cap of $8.46 billion, a PE ratio of -10.06 and a beta of 1.12.

Revolution Medicines (NASDAQ:RVMD - Get Free Report) last issued its earnings results on Wednesday, August 6th. The company reported ($1.31) earnings per share for the quarter, missing the consensus estimate of ($0.94) by ($0.37). During the same quarter last year, the business posted ($0.81) EPS. Revolution Medicines's revenue for the quarter was up .0% on a year-over-year basis. Analysts forecast that Revolution Medicines, Inc. will post -3.49 earnings per share for the current year.

Wall Street Analysts Forecast Growth

RVMD has been the topic of a number of recent analyst reports. Wedbush boosted their price target on shares of Revolution Medicines from $73.00 to $77.00 and gave the company an "outperform" rating in a research report on Thursday, September 11th. Wells Fargo & Company boosted their price target on shares of Revolution Medicines from $67.00 to $70.00 and gave the company an "overweight" rating in a research report on Thursday, September 11th. Piper Sandler initiated coverage on shares of Revolution Medicines in a research report on Monday, August 18th. They issued an "overweight" rating and a $75.00 price target on the stock. Truist Financial initiated coverage on shares of Revolution Medicines in a research report on Friday, September 5th. They issued a "buy" rating and a $99.00 price target on the stock. Finally, Guggenheim restated a "buy" rating and issued a $80.00 price target on shares of Revolution Medicines in a research report on Wednesday, June 25th. One research analyst has rated the stock with a Strong Buy rating and fourteen have assigned a Buy rating to the stock. According to MarketBeat, Revolution Medicines presently has an average rating of "Buy" and an average price target of $73.67.

Hedge Funds Weigh In On Revolution Medicines

Institutional investors have recently modified their holdings of the stock. Lunate Capital Ltd bought a new stake in shares of Revolution Medicines during the first quarter worth approximately $77,658,000. Norges Bank bought a new stake in shares of Revolution Medicines during the second quarter worth approximately $62,584,000. T. Rowe Price Investment Management Inc. bought a new stake in shares of Revolution Medicines during the first quarter worth approximately $59,173,000. Nextech Invest Ltd. raised its stake in shares of Revolution Medicines by 20.7% during the fourth quarter. Nextech Invest Ltd. now owns 7,601,087 shares of the company's stock worth $332,472,000 after buying an additional 1,304,347 shares during the last quarter. Finally, Vestal Point Capital LP bought a new stake in shares of Revolution Medicines during the second quarter worth approximately $44,148,000. 94.34% of the stock is owned by institutional investors.

About Revolution Medicines

Revolution Medicines, Inc, a clinical-stage precision oncology company, develops novel targeted therapies for RAS-addicted cancers. The company's research and development pipeline comprises RAS(ON) inhibitors designed to be used as monotherapy in combination with other RAS(ON) inhibitors and/or in combination with RAS companion inhibitors or other therapeutic agents, and RAS companion inhibitors for combination treatment strategies.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.